Quarterly report · Q1
7733.TEDINET S100RLNN
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥207.7bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥192.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥44.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥19.7bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥42.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥240.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥240.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.69T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.51T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.43T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥781.3bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥867.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥906.9bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥582.2bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥905.9bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥581.1bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥558.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥169.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥286.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥53.1bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥26.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥427.0bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥25.9bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥21.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥191.9 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.53 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥191.5 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.52 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 53.7% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 40.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥9.2bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥141m |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥9.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥31.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥24.8bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥296m |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥13.4bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥37.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 629
| Item | Context | Value | Unit |
|---|---|---|---|
| Sales to external customers IFRS | Prior1YTDDuration | 192265000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 102000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 102000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -102000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration | － | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 116857000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 72365000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3145000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 192367000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -102000000 | JPY |
| Net sales IFRS | Prior1YTDDuration | 192265000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 24834000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 13357000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | -296000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 37895000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | 6626000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 44521000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 718000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 3191000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 42048000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 37000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReportableSegmentsMember | 37000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 37000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 9167000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 4793000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 331000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReportableSegmentsMember | 14291000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReconcilingItemsMember | 1475000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration | 15766000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 333000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 388000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReportableSegmentsMember | 721000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration | 721000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 127138000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 77156000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3429000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 207723000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | CurrentYTDDuration | 207723000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 36000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 36000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |